ArticleFrontiers in immunology2026
Systemic IgG responses to
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: American tegumentary leishmaniasis (ATL) caused by Leishmania braziliensis is characterized by marked clinical and immunopathological heterogeneity. While cellular immune responses have been extensively investigated, the contribution of humoral immunity, particularly against parasite-derived extracellular vesicles (EVs) components, remains poorly understood. Here, we evaluated systemic IgG responses against EVs derived from L. braziliensis isolates associated with distinct clinical forms of ATL and assessed their association with disease presentation and therapeutic outcome. Methods: Serum samples from patients with cutaneous leishmaniasis (CL), mucosal leishmaniasis (ML), disseminated leishmaniasis (DL), early cutaneous leishmaniasis (ECL), and healthy subjects were analyzed by ELISA using intact EVs. Results and discussion: CL patients exhibited higher anti-EV IgG levels than healthy subjects, confirming the induction of EV reactive humoral responses during active disease. Comparative analysis revealed that CL and DL patients displayed higher anti-EV IgG levels than ML patients, whereas ECL patients exhibited lower levels than classical CL, consistent with reduced systemic humoral responses at early stages of infection. IgG responses against EVs derived from different isolates were strongly correlated, indicating shared antigenic determinants exposed on the vesicle surface. Higher baseline IgG levels against EV surface antigens were associated with clinical cure at day 60 following antimonial therapy but did not predict outcome at day 90, suggesting a relationship with early healing dynamics rather than definitive lesion resolution. Anti-DL EV IgG levels showed a weak correlation with time to lesion healing. In contrast, short-term in vitro stimulation of peripheral blood mononuclear cells with EVs did not alter circulating B cell subset distribution. Together, these findings demonstrate that L. braziliensis-derived EVs are immunologically relevant targets of systemic humoral responses in humans and that IgG reactive to EVs profiles reflect clinical form and early therapeutic response. EV-based serological analyses may therefore provide complementary insights into immune dynamics and disease progression in ATL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.